Success Metrics

Clinical Success Rate
43.2%

Based on 19 completed trials

Completion Rate
43%(19/44)
Active Trials
7(13%)
Results Posted
184%(35 trials)
Terminated
25(45%)

Phase Distribution

Ph phase_1
17
31%
Ph phase_2
18
33%
Ph phase_4
2
4%
Ph phase_3
14
25%

Phase Distribution

17

Early Stage

18

Mid Stage

16

Late Stage

Phase Distribution51 total trials
Phase 1Safety & dosage
17(33.3%)
Phase 2Efficacy & side effects
18(35.3%)
Phase 3Large-scale testing
14(27.5%)
Phase 4Post-market surveillance
2(3.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

40.4%

19 of 47 finished

Non-Completion Rate

59.6%

28 ended early

Currently Active

7

trials recruiting

Total Trials

55

all time

Status Distribution
Active(7)
Completed(19)
Terminated(28)
Other(1)

Detailed Status

Terminated25
Completed19
Recruiting4
Active, not recruiting3
Withdrawn3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
55
Active
7
Success Rate
43.2%
Most Advanced
Phase 4

Trials by Phase

Phase 117 (33.3%)
Phase 218 (35.3%)
Phase 314 (27.5%)
Phase 42 (3.9%)

Trials by Status

completed1935%
active_not_recruiting35%
recruiting47%
terminated2545%
withdrawn35%
unknown12%

Recent Activity

Clinical Trials (55)

Showing 20 of 55 trialsScroll for more
NCT04666038Phase 3

Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active Not Recruiting
NCT06846671Phase 3

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Recruiting
NCT07218341Phase 4

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
NCT07139873Phase 3

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

Recruiting
NCT02135133Phase 2

A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL

Completed
NCT02970318Phase 3

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Active Not Recruiting
NCT02787369Phase 1

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

Active Not Recruiting
NCT02457598Phase 1

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Terminated
NCT03890289Phase 2

Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma

Terminated
NCT06205290Phase 3

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Withdrawn
NCT03878524Phase 1

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated
NCT03257722Phase 1

Pembrolizumab + Idelalisib for Lung Cancer Study

Terminated
NCT02332980Phase 2

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Completed
NCT04699461Phase 2

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma

Terminated
NCT02962401Phase 2

Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia

Completed
NCT02536300Phase 3

Dose Optimization Study of Idelalisib in Follicular Lymphoma

Terminated
NCT05725200Phase 2

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Recruiting
NCT02968563Phase 2

Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Completed
NCT02639910Phase 2

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

Completed
NCT03568929

Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma

Completed

Drug Details

Intervention Type
DRUG
Total Trials
55